- Product
- 7 out of 10 doctors exposed to patient violence
- by Kang, Shin-Kook Nov 15, 2019 06:29am
- Apparently, seven out of ten doctors have faced verbal abuse or physical violence against them by a patient or their family. On Nov. 13, Korean Medical Association (KMA, President Choi Dae-zip) published a result of an urgent survey conducted on 2,034 member doctors of the organization. The survey result found among 1,455 doctors (71.5 p
- Product
- Vibramycin restocking delayed again, but for how long?
- by Kim, Min-Gun Nov 10, 2019 09:58pm
- Restocking of Pifzer Korea’s antibiotic Vibramycin-N (doxycycline) 100mg (500T), initially scheduled in November, has been delayed again. Since July last year, this is an eighth supply delay notice. Number of pharmacies is to experience inconvenience due to the delay. On November 5, Pfizer Korea notified all drug distribution companie
- Product
- Lixiana joins NOAC market race late but takes the lead
- by Byun Kyung A Oct 31, 2019 09:59am
- A follow-on drug in the non-vitamin K antagonist oral anticoagulant (NOAC) market, Lixiana, continues to lead the market. The treatment took the lead from Xarelto in last January for the first time, and it has been the most prescribed drug in the market for nine consecutive months. Pfizer and Bristol-Myers Squibb’s Eliquis had to face a Ko
- Product
- Maviret takes up 83% of HCV treatment market share
- by Byun Kyung A Oct 31, 2019 09:41am
- Abbvie broke through the hepatitis C virus (HCV) treatment market and dominated 83 percent of oral outpatient prescription market only with its pan-genotype HCV treatment, Maviret, launched last year. Gilead once dominated the market with two items, but their prescription ratio shriveled down to 12 percent. On Oct. 30, a pharmaceutic
- Product
- Government likely to list Zejula in December
- by Byun Kyung A Oct 31, 2019 09:36am
- Sources predict Zejula, an ovarian cancer treatment, would get listed for healthcare reimbursement in coming December. According to an industry insider on Oct. 16, Takeda Pharmaceuticals Korea is waiting for Health Insurance Policy Deliberation Committee’s (HIPDC) deliberation, after recently reaching an agreement with National Health
- Product
- Listing first-line lung cancer treatment Tagrisso 'deferred'
- by Byun Kyung A Oct 31, 2019 09:35am
- A first-line anticancer therapy, Tagrisso could struggle to get listed for NHI reimbursement. An industry insider reported on Oct. 17, Health Insurance Review and Assessment Service (HIRA) Cancer Disease Deliberation Committee decided to ‘defer’ on the decision to list Tagrisso (osimertinib), a third generation Epidermal Growth Factor
